‘Cancer doesn’t have an age’: Genetic testing and cancer risk management inBRCA1/2mutation-positive women aged 18–24
- 30 April 2012
- journal article
- research article
- Published by SAGE Publications in Health: An Interdisciplinary Journal for the Social Study of Health, Illness and Medicine
- Vol. 16 (6), 636-654
- https://doi.org/10.1177/1363459312442420
Abstract
Increasingly, 18–24-year-old women from hereditary breast/ovarian cancer (HBOC) families are pursuing genetic testing, despite their low absolute risks of breast and ovarian cancer and the fact that evidence-based management options used with older high-risk women are not generally available. Difficult clinical decisions in older carriers take on substantially more complexity and value-laden import in very young carriers. As a result, many of the latter receive highly personal and emotionally charged cancer risk information in a life context where management strategies are not well defined. We analyzed 32 in-depth interviews with BRCA1/2 mutation-positive women aged 18–24 using techniques of grounded theory and interpretive description. Participants described feeling vulnerable to a cancer diagnosis but in a quandary regarding their care because evidence-based approaches to management have not been developed and clinical trials have not been undertaken. Our participants demonstrated a wide range of genetic and health literacy. Inconsistent recommendations, surveillance fatigue, and the unpredictability of their having health insurance coverage for surgical risk-reducing procedures led several to contemplate risk-reducing mastectomy before age 25. Parents remained a primary source of emotional and financial support, slowing age-appropriate independence and complicating patient privacy. Our findings suggest that, for 18–24-year-olds, readiness to autonomously elect genetic testing, to fully understand and act on genetic information, and to confidently make decisions with life-long implications are all evolving processes. We comment on the tensions between informed consent, privacy, and the unique developmental needs of BRCA1/2 mutation-positive women just emerging into their adult years.This publication has 48 references indexed in Scilit:
- Identification and Management of Women With BRCA Mutations or Hereditary Predisposition for Breast and Ovarian CancerMayo Clinic Proceedings, 2010
- Beliefs About Heritability of Cancer and Health Information Seeking and Preventive BehaviorsJournal of Cancer Education, 2009
- Hereditary ovarian carcinoma: Heterogeneity, molecular genetics, pathology, and managementMolecular Oncology, 2009
- Life Trajectories, Genetic Testing, and Risk Reduction Decisions in 18–39 Year Old Women at Risk for Hereditary Breast and Ovarian CancerJournal of Genetic Counseling, 2008
- Risk-Reducing Salpingo-Oophorectomy for the Prevention of BRCA1- and BRCA2-Associated Breast and Gynecologic Cancer: A Multicenter, Prospective StudyJournal of Clinical Oncology, 2008
- Role of Parenting Relationship Quality in Communicating about Maternal BRCA1/2 Genetic Test Results with ChildrenJournal of Genetic Counseling, 2008
- Meta-Analysis of BRCA1 and BRCA2 PenetranceJournal of Clinical Oncology, 2007
- Characterization ofBRCA1andBRCA2Mutations in a Large United States SampleJournal of Clinical Oncology, 2006
- Decision making and decision support for hereditary breast-ovarian cancer susceptibility.Health Psychology, 2005
- Choice as a risk to women's healthHealth, Risk & Society, 1999